Human CD62L- memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells:: potential for adoptive immunotherapy and allodepletion

被引:85
作者
Foster, AE
Marangolo, M
Sartor, MM
Alexander, SI
Hu, M
Bradstock, KF
Gottlieb, DJ [1 ]
机构
[1] Westmead Hosp, Dept Med, Westmead, NSW 2145, Australia
[2] Univ Sydney, Dept Med, Sydney, NSW 2006, Australia
[3] Childrens Hosp, Ctr Kidney Res, Westmead, NSW, Australia
[4] Westmead Hosp, Marrow Transplant Serv, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead, NSW 2145, Australia
关键词
D O I
10.1182/blood-2003-12-4431
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Selective depletion of alloreactive T cells from allogeneic stem cell grafts can reduce graft-versus-host disease (GVHD) while preserving beneficial effects of T cells including facilitation of engraftment, protection against opportunistic infection, and reduced relapse risk. Memory T cells (CD62L(-)) represent a population of T cells that have previously encountered pathogens and may contain fewer T cells capable of recognizing neoantigens including recipient allogeneic antigen (aAg). We investigated whether human naive (CD62L(+)) or memory (CD62L(-)) T cells had different capacities to respond to aAg by assessing their ability to proliferate in response to and lyse HLA-mismatched Epstein-Barr virus-transformed B cells, Freshly sorted and in vitro expanded CD62L(-) memory T cells were less responsive to aAg stimulation than were CD62L(+) naive T cells but contained higher levels of cytomegalovirus (CMV)-specific T cells. Analysis of T cell receptor (TCR) repertoire showed restricted TCR diversity in the memory T-cell population possibly due to selection associated with chronic exposure to common pathogens. Memory T cells may represent a donor cell subpopulation suitable for enhancing immune reconstitution without increasing the risk of GVHD. (C) 2004 by The American Society of Hematology.
引用
收藏
页码:2403 / 2409
页数:7
相关论文
共 39 条
[1]   Selective depletion of donor alloreactive T cells without loss of antiviral or antileukernic responses [J].
Amrolia, PJ ;
Muccioli-Casadei, G ;
Yvon, E ;
Huls, H ;
Sili, U ;
Wieder, ED ;
Bollard, C ;
Heslop, HE ;
Molldrem, JJ ;
Rooney, CM ;
Brenner, MK .
BLOOD, 2003, 102 (06) :2292-2299
[2]   Memory CD4+ T cells do not induce graft-versus-host disease [J].
Anderson, BE ;
McNiff, J ;
Yan, J ;
Doyle, H ;
Mamula, M ;
Shlomchik, MJ ;
Shlomchik, WD .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (01) :101-108
[3]   Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation:: a phase 1/2 study [J].
André-Schmutz, I ;
Le Deist, F ;
Hacein-Bey-Abina, S ;
Vitetta, E ;
Schindler, J ;
Chedeville, G ;
Vilmer, E ;
Fischer, A ;
Cavazzana-Calvo, M .
LANCET, 2002, 360 (9327) :130-137
[4]   In vivo-activated CD4 T cells upregulate CXC chemokine receptor 5 and reprogram their response to lymphoid chemokines [J].
Ansel, KM ;
McHeyzer-Williams, LJ ;
Ngo, VN ;
McHeyzer-Williams, MG ;
Cyster, JG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (08) :1123-1134
[5]   Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections [J].
Appay, V ;
Dunbar, PR ;
Callan, M ;
Klenerman, P ;
Gillespie, GMA ;
Papagno, L ;
Ogg, GS ;
King, A ;
Lechner, F ;
Spina, CA ;
Little, S ;
Havlir, DV ;
Richman, DD ;
Gruener, N ;
Pape, G ;
Waters, A ;
Easterbrook, P ;
Salio, M ;
Cerundolo, V ;
McMichael, AJ ;
Rowland-Jones, SL .
NATURE MEDICINE, 2002, 8 (04) :379-385
[6]   TRANSFER OF THE HSV-TK GENE INTO DONOR PERIPHERAL-BLOOD LYMPHOCYTES FOR IN-VIVO MODULATION OF DONOR ANTITUMOR IMMUNITY AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
BORDIGNON, C ;
BONINI, C ;
VERZELETTI, S ;
NOBILI, N ;
MAGGIONI, D ;
TRAVERSARI, C ;
GIAVAZZI, R ;
SERVIDA, P ;
ZAPPONE, E ;
BENAZZI, E ;
BERNARDI, M ;
PORTA, F ;
FERRARI, G ;
MAVILIO, F ;
ROSSINI, S ;
BLAESE, RM ;
CANDOTTI, F .
HUMAN GENE THERAPY, 1995, 6 (06) :813-819
[7]   Transfer of aflogeneic CD62L- memory T cells without graft-versus-host disease [J].
Chen, BJ ;
Cui, XY ;
Sempowski, GD ;
Liu, CX ;
Chao, NJ .
BLOOD, 2004, 103 (04) :1534-1541
[8]  
CHEN BJ, 2003, BLOOD 1009, DOI DOI 10.1182/BLOOD-2003-08-2987
[9]   CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation [J].
Edinger, M ;
Hoffmann, P ;
Ermann, J ;
Drago, K ;
Fathman, CG ;
Strober, S ;
Negrin, RS .
NATURE MEDICINE, 2003, 9 (09) :1144-1150
[10]   Both CD4+CD25+ and CD4+CD25- regulatory cells mediate dominant transplantation tolerance [J].
Graca, L ;
Thompson, S ;
Lin, CY ;
Adams, E ;
Cobbold, SP ;
Waldmann, H .
JOURNAL OF IMMUNOLOGY, 2002, 168 (11) :5558-5565